| 生物活性 | |||
|---|---|---|---|
| 靶点 | 
 | ||
| 描述 | Vicriviroc maleate is a CCR5 antagonist with IC50 of 0.91 nM in clinical development for the treatment of HIV-1. | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 | 
| NCT00551330 | HIV Infections ... 展开 >> Acquired Immunodeficiency Syndrome 收起 << | Phase 2 | Completed | - | - | 
| NCT00705419 | - | Completed | - | - | |
| NCT00243230 | HIV Infections | Phase 2 | Completed | - | - | 
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
| 1 mM 5 mM 10 mM | 1.54mL 0.31mL 0.15mL | 7.70mL 1.54mL 0.77mL | 15.39mL 3.08mL 1.54mL | 
| 参考文献 | 
|---|